[-] madjelly1 | 2 points | Nov 03 2020 09:34:08

Hello, do you have list or spreadsheet for ivermectin trials? Could you please share it?

[-] Haitchpeasauce | 2 points | Nov 03 2020 13:27:56

This site contains some of the studies as a starting point: https://c19ivermectin.com/

[-] TrumpLyftAlles | 1 points | Nov 03 2020 16:43:17

Excellent site! That's where I found this study.

[-] TrumpLyftAlles | 1 points | Nov 03 2020 07:34:10

Put this study in the WIN column for ivermectin + doxycycline. 💖

This trial was registered here on 2020-10-19 and written up on the sub here. The study description from that post:

N=140, random assignment, singly-blinded (outcomes assessor), not placebo-controlled.

Treatment:

* Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose.

* Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard of care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.

Treatment and control groups received standard care:

* Acetaminophen 500mg on need
* Vitamin C 1000mg twice/ day
* Zinc 75-125 mg/day
Vitamin D3 5000IU/day
Azithromycin 250mg/day for 5 days
Oxygen therapy/ C-Pap if needed
dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed
* Mechanical ventilation, if needed

Primary outcome measures:

* 1) Mortality rate (Time frame: 8 weeks)
* 2) Rate of progression to a more advanced stage (Time frame: 8 weeks)

Secondary outcome:

* 1) Time to recovery (symptom-free or PCR-) (Time frame: 8 weeks)

Ages: 18 - 86

Location: Baghdad, Iraq

From the study report PDF:

Abstract

Objectives:
COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try repurposed old drugs on COVID-19.

Methods:
Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg PO of Ivermectin per day for 2-3 days along with 100mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy. The time to recovery, the progression of the disease, and the mortality rate were the outcome-assessing parameters.

If the subjects were randomly-assigned, then why are there 11 critical patients in the treatment arm and none in the control arm? Also severe patients: 11 in treatment, 22 in control. ??

Results:
Among all patients and among severe patients, 3/70 (4.28%) and 1/11 (9%), respectively progressed to a more advanced stage of the disease in the Ivermectin Doxycycline group versus 7/70 (10%) and 7/22 (31.81%), respectively in the control group (P0.05). The mortality rate was 0/48 (0%), 0/11 (0%), and 2/11 (18.2%) in mild-moderate, severe, and critical COVID-19 patients, respectively in IvermectinDoxycycline group versus 0/48 (0%), and 6/22 (27.27%) in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (p=0.052). Moreover, the mean time to recovery was 6.34, 20.27, and 24.13 days in mild-moderate, severe, and critical COVID-19 patients, respectively in Ivermectin*-Doxycycline group versus 13.66 and 24.25 days in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (P<0. 01).

Conclusions:
Ivermectin with doxycycline reduced the time to recovery and the percentage of patients who progress to more advanced stage of disease; in addition, Ivermectin with doxycycline reduced mortality rate in severe patients from 22.72% to 0%; however, 18.2% of critically ill patients died with Ivermectin and doxycycline therapy. Taken together, the earlier administered Ivermectin with doxycycline, the higher rate of successful therapy.

Results table

Ivermectin + doxycycline was beneficial for every outcome: reduced time to recovery, progression of disease, and mortality. However, there were only two measures that were statistically significant at the .05 level:

Time to recovery:
Total (all subjects): 10.61 days vs 17.9 days (p < 0.0001)
Mild-moderate subjects: 6.34 days vs 13.66 days (p < 0.0001)

Reduction of mortality for severe patients was almost statsig: 0/11 vs 6/22 (p = 0.052)

The other outcome measures had p-values ranging from 0.14 to 0.29.

With a larger N, the treatment would have been statistically significant on the other outcome measures. It's too bad they didn't do a larger study. Placebo-control would have been nice, too.

Note that all patients received zinc and vitamins C and D, so this trial tested the Borody "triple therapy" (that has five components) 6 months before the Borody trial is supposed to be done. Borody has N=300, so it should find more statistically-significant results.

I tweeted about the study (always trying to get the word out!).

Good study, good result! 👍

[-] Haitchpeasauce | 3 points | Nov 03 2020 07:39:26

The paper says that for ethical reasons none of the critical patients were placed into the non-treatment arm. Of those critically ill patients, two died. Under standard care this number would be higher.

[-] TrumpLyftAlles | 2 points | Nov 03 2020 08:54:56

Thanks for catching that!

Any explanation for the non-random distribution of severe patients?

What time is it in Oz? It's 4:00 AM here in Boston. Good-night!

Edit: They must have over-allocated the severe cases to the control group to make it 70/70.

[-] TrumpLyftAlles | 1 points | Nov 03 2020 08:39:49

Other takes on the study from twitter:

"Taken together, the earlier administered Ivermectin with doxycycline, the higher rate of successful therapy."

Even if efficacy is uncertain, if harm will not be caused, why not use it before patients are ill?

Surely better than no treatment at all?

Primary outcome measure of Number of Patients with Early Clinical Improvement that 111 out of 180 (60.7%) in the active study drug group achieved that milestone while 80 out 180 (44.4%) in the placebo group wound up in this category.

Iv+doxy reduced time to recovery and the % of pts who progress to more advanced stage of disease; in addition, Iv+doxy reduced mortality rate in severe pts from 22.72%. Taken together, earlier administered Iv + doxy, the higher rate of successful therapy.

Underpowered RCT for doxycycline and ivermectin combination treatment for COVID-19 of various degrees of severity in Iraq shows faster recovery time for the experimental group.

67% lower mortality with ivermectin-doxycycline, p=0.27.

Small RCT showing reduced time to recovery and reduced mortality with treatment.

Greater effectiveness for earlier treatment.

Ivermectina + Doxiciclina:

Lower Mortality rate.
Lower Recovery time.
Lower Disease progression.

Ivermectin+doxycycline reduced the time to recovery and the % patients who progress to advanced stage of disease. Ivermectin+doxycycline reduced mortality rate in severe patients from 22.72% to 0%. The earlier administered the higher rate of success.

Controlled randomized clinical trial on using #Ivermectin with #Doxycycline for treating #COVID19 patients in Baghdad, Iraq

Ivermectin with doxycycline reduced the time to recovery and the percentage of patients who progress to advanced stage of disease. Study in 70 patients that found that the use of invermectin in combination with doxycycline reduces the recovery time and mortality of COVID-19 patients.

Results suggesting the effectiveness of ivermectin from Iraq! If you are suspicious, do PCR immediately, and if it is positive, immediately administer ivermectin. Consider administration of dexamethasone and actemra as needed.